Please assess the completion status of the following clinical trial:

Trial Title: Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 10 to ≤ 17 years of age (before 18th birthday)~* Diagnosis of heterozygous familial hypercholesterolemia~* On an approved statin with stable optimized dose for ≥ 4 weeks~* Other lipid-lowering therapy stable for ≥ 4 weeks (fibrates must be stable for ≥ 6 weeks)~* Fasting LDL-C ≥ 130 mg/dL (3.4 mmol/L)~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~* Type 1 diabetes, or type 2 diabetes that is or poorly controlled~* Uncontrolled hyperthyroidism or hypothyroidism~* Cholesterylester transfer protein (CETP) inhibitor in the last 12 months, or mipomersen or lomitapide in the last 5 months~* Previously received evolocumab or any other investigational therapy to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9).~* Lipid apheresis within the last 12 weeks prior to screening.~* Homozygous familial hypercholesterolemia

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching subcutaneous injection every 4 weeks (QM)
- EvoMab 420 mg QM (Type: EXPERIMENTAL): Evolocumab subcutaneous injection QM

Based on this trial design, predict the completion outcome and termination type (if applicable).